Structure Therapeutics Inc.

Structure Therapeutics Inc.

GPCR · Nasdaq

Structure Therapeutics Inc. (GPCR) is a Biotechnology company in the Healthcare sector, listed on Nasdaq. This page provides the complete earnings calendar, dividend schedule, and financial data for Structure Therapeutics Inc. in 2026. The next earnings report is expected on November 18, 2026.

Earnings calendar

Next earnings date

18 Nov 2026

In 91 days

EPS estimate

-0.28

Revenue estimate

50.0M

Past earnings

06 Aug 2026
EPS actual
-0.44 (-4.5%)
estimate -0.42
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
07 May 2026
EPS actual
-0.35 (+0.3%)
estimate -0.35
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
26 Feb 2026
EPS actual
0.17 (+397.1%)
estimate -0.06
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
Beat Miss usd

Latest earnings analysis

Structure Therapeutics Inc. missed consensus on EPS, delivering a loss per share of $0.435 versus an estimated loss of $0.4163, while revenue met expectations at $0. In the prior quarter, EPS came in slightly ahead of estimates and revenue also met expectations.

Dividend calendar

No dividend history available.

EPS (Earnings Per Share)

Revenue

Company profile

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Exchange
Nasdaq
CEO
Raymond C. Stevens
Employees
163
IPO date
03 Feb 2023
ISIN
US86366E1064
Website
structuretx.com

Frequently asked questions

When does Structure Therapeutics Inc. (GPCR) next report earnings?

Structure Therapeutics Inc. (GPCR) is scheduled to report earnings on November 18, 2026.

What was Structure Therapeutics Inc.'s most recent earnings date?

Structure Therapeutics Inc. (GPCR) last reported earnings on August 6, 2026.

Where is Structure Therapeutics Inc. stock listed?

Structure Therapeutics Inc. (GPCR) is listed on Nasdaq.